Nuvig Launches Clinical Development for NVG-2089, its Latest Immune Modulator
Monday, February 12, 2024
Nuvig Therapeutics, Inc. ("Nuvig"), a privately held biotech company, has announced the commencement of human trials for NVG-2089, its proprietary product. The therapy targets inflammatory myopathies and severe dermatologic autoimmune diseases. Additionally, Nuvig has disclosed that the FDA granted fast track designation (FTD) for NVG-2089's development in bullous pemphigoid.
NVG-2089 is an innovative approach as a recombinant, non-immunosuppressive immunomodulator, designed to interact with type II Fc receptors. It aims to activate an internal regulatory mechanism that mitigates autoimmune dysregulation. In preclinical studies, NVG-2089 has demonstrated potent anti-inflammatory effects in animal models characterized by activated B cells, T cells, and specific myeloid immune cells. Encouragingly, NVG-2089 has shown favorable tolerability in animal toxicology assessments.
Nuvig Therapeutics' CEO, expressed enthusiasm about progressing NVG-2089's clinical development, highlighting its potential in addressing various autoimmune diseases. The initial study will primarily focus on evaluating the safety and tolerability of NVG-2089, with secondary objectives including assessing its pharmacokinetics and pharmacodynamics. Upon the completion of Phase 1, Nuvig intends to proceed with proof-of-concept investigations in patients suffering from inflammatory myopathies and severe dermatologic autoimmune conditions.
Source: businesswire.com
